Among the gene mutations acquired in the metastatic counterparts, the most frequently affected pathways (PIK3/AKT/MTOR, epigenetic, cell cycle, and WNT/β-catenin) might confer a selective advantage to cancer metastasis formation including hormone resistance. This evidence concerns the gene MTOR and cancer.